XML 58 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Product and Geographic Sales Information (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Revenue by reportable segment
The tables below show the Company’s disaggregated revenue for the periods presented:
Three Months Ended March 31,
20212020
Subscription revenues$235,092 $193,235 
Transactional revenues84,177 49,239 
Re-occurring revenues112,185 — 
Total revenues, gross431,454 242,474 
Deferred revenues adjustment(1)
(3,024)(1,882)
Total revenues, net$428,430 $240,592 
(1) Reflects the deferred revenue adjustment as a result of purchase accounting.
The following table summarizes revenue by reportable segment for the periods indicated:
Three Months Ended March 31,
20212020
Science Segment$191,288 $145,694 
Intellectual Property Segment
237,142 94,898 
Total Revenues$428,430 $240,592 
Schedule of Segment Reporting Information, by Segment
Adjusted EBITDA by segment
The following table presents segment profitability and a reconciliation to net income for the periods indicated:
Three Months Ended March 31,
2021
(As Restated)
2020
(As Restated)
Science Segment Adjusted EBITDA
$90,594 $63,954 
Intellectual Property Segment Adjusted EBITDA
74,239 14,268 
Total Adjusted EBITDA
$164,833 $78,222 
Benefit (provision) for income taxes
(263)(14,753)
Depreciation and amortization
(131,654)(51,441)
Interest, net
(37,393)(30,940)
Transition services agreement costs
— (1,551)
Transition, transformation and integration expense
(46)(2,228)
Deferred revenues adjustment
(3,024)(1,882)
Transaction related costs
22,924 (26,689)
Share-based compensation expense
(39,020)(17,469)
Restructuring and impairment
(67,895)(7,754)
Mark to market adjustment on financial instruments51,215 (55,632)
Other
(15,628)2,484 
Net income attributable to Clarivate
$(55,951)$(129,633)